{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T02:13:40Z","timestamp":1777947220822,"version":"3.51.4"},"reference-count":0,"publisher":"S. Karger AG","license":[{"start":{"date-parts":[[2009,3,31]],"date-time":"2009-03-31T00:00:00Z","timestamp":1238457600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"},{"start":{"date-parts":[[2009,3,31]],"date-time":"2009-03-31T00:00:00Z","timestamp":1238457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Skin Pharmacol"],"abstract":"<jats:p>Repeated open application of clobetasol 17-propionate cream and ointment to normal skin over a period of 6 weeks induced an increase in skin surface roughness as assessed by profilometry (p &lt; 0.05), while 6 weeks\u2019 application of triamcinolone acetonide cream and ointment did not. The increase in skin roughness with clobetasol 17-propionate cream turned out to be greater than with ointment containing identical amounts of clobetasol 17-propionate (p &lt; 0.05). A clear-cut correlation between increase of skin surface roughness and skin thickness as assessed by high-frequency ultrasound could be demonstrated only with clobetasol 17-propionate cream and ointment.<\/jats:p>","DOI":"10.1159\/000211407","type":"journal-article","created":{"date-parts":[[2009,4,2]],"date-time":"2009-04-02T10:14:27Z","timestamp":1238667267000},"page":"120-123","source":"Crossref","is-referenced-by-count":3,"title":["0.05% Clobetasol 17-Propionate Cream and Ointment but Not the Corresponding 0.1 % Triamcinolone Acetonide Preparations Increase Skin Surface Roughness: A Possible Dissociation of Unwanted Epidermal and Dermal Effects"],"prefix":"10.1159","author":[{"given":"M.J.","family":"Kerscher","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.C.","family":"Korting","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Mehringer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"M\u00e4tzig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2009,3,31]]},"container-title":["Skin Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/211407","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/karger.com\/article-pdf\/doi\/10.1159\/000211407","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T22:41:25Z","timestamp":1777761685000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000211407"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,3,31]]},"references-count":0,"URL":"https:\/\/doi.org\/10.1159\/000211407","archive":["Portico"],"relation":{},"ISSN":["1011-0283","2571-7162"],"issn-type":[{"value":"1011-0283","type":"print"},{"value":"2571-7162","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,3,31]]}}}